#ESCcongress
LightNews LightNews
womenasone.bsky.social
At RISE @ ESC Congress 2026, industry leaders shared how women can access research opportunities through visibility, connections & expertise and the importance of developing inclusive clinical trials.

Reflect on the discussion: womenasone.org/lates...

#LetsRISE26 #ESCCongress #CardioSky
November 2, 2026 at 4:24 PM
nejm.org
Among patients with syncope that remained unexplained after evaluation in the ED, immediate initiation of 14-day ECG monitoring did not result in significantly fewer patient-reported syncope episodes at 1 year than standard care. Full ASPIRED trial results: https://nej.md/4wH7SJh

#ESCCongress
This image contains an excerpt from the Research Summary "Immediate Ambulatory Electrocardiographic Monitoring in Syncope" published in the New England Journal of Medicine. It includes a silhouette of a patient with syncope and an ECG line. It also highlights patient statistics: 2234 adults, mean age 58, with 52% male and 48% female. Below are comparisons of two groups: "Ambulatory ECG Monitoring" with 1123 participants and "Standard Care" with 1111 participants. A prompt to read the full Research Summary at NEJM.org sits at the bottom.
November 2, 2026 at 4:00 PM
nejm.org
The ASPIRED trial tested early cardiac monitoring initiated after emergency evaluation of patients with unexplained syncope. Research findings are summarized in a new Quick Take video. https://nej.md/4yKjz2I

#ESCCongress
A visual representation of the ASPIRED trial, which tested the effects of early cardiac monitoring, initiated at the index visit to the emergency department, on the number of subsequent patient-reported episodes of syncope.
October 30, 2026 at 7:00 PM
womenasone.bsky.social
RISE @ ESC Congress 2026 brought together world-leading experts to share ideas, challenge perspectives & discuss actionable steps toward equity in cardiology.

Hear attendees reflect on the value of being present for & contributing to these conversations

#LetsRISE26 #ESCCongress #CardioSky
October 28, 2026 at 3:02 PM
herzmedizin.bsky.social
#ESCCongress 2026: Dieses Jahr gab es drei neue europäische Guidelines:
1. Herzinsuffizienz
2. CVD & CKD
3. Kardiologische Rehabilitation
Kommentiert von Prof. J. Bauersachs, Prof. L. Maier und PD Dr. A. Dietl, Prof. N. Marx & Prof. B. Schwaab.
➡️ herzmedizin.de/fuer-...
#Herzmedizinde #DGK
ESC Congress 2026, München
ESC Congress 2026 | Hier finden Sie unsere Berichterstattung zum Kongress in München: Vorberichte, Fachbeiträge und Analysen zu ausgewählten Studien.
herzmedizin.de
October 23, 2026 at 2:31 PM
herzmedizin.bsky.social
#ESCCongress 2026: Dieses Jahr gab es drei neue europäische Guidelines:
1. Herzinsuffizienz
2. CVD & CKD
3. Kardiologische Rehabilitation
Kommentiert von Prof. J. Bauersachs, Prof. L. Maier und PD Dr. A. Dietl, Prof. N. Marx & Prof. B. Schwaab.
➡️ herzmedizin.de/fuer-aerzte-...
#Herzmedizinde #DGK
ESC Congress 2026, München
ESC Congress 2026 | Hier finden Sie unsere Berichterstattung zum Kongress in München: Vorberichte, Fachbeiträge und Analysen zu ausgewählten Studien.
herzmedizin.de
October 23, 2026 at 10:25 AM
dgk-org.bsky.social
#ESCCongress 2026: Dieses Jahr gab es drei neue europäische Guidelines:
1. Herzinsuffizienz
2. CVD & CKD
3. Kardiologische Rehabilitation
Kommentiert von Prof. J. Bauersachs, Prof. L. Maier und PD Dr. A. Dietl, Prof. N. Marx & Prof. B. Schwaab.
➡️ herzmedizin.de/fuer-aerzte-...
#Herzmedizinde #DGK
ESC Congress 2026, München
ESC Congress 2026 | Hier finden Sie unsere Berichterstattung zum Kongress in München: Vorberichte, Fachbeiträge und Analysen zu ausgewählten Studien.
herzmedizin.de
October 22, 2026 at 9:21 AM
womenasone.bsky.social
Building a more equitable future in cardiology takes connection, collaboration, and a community where women know they belong and can thrive.

That's what we're building at Women As One. Hear how RISE @ ESC Congress 2026 supports that ⬇️

#LetsRISE26 #ESCCongress #CardioSky @escardio.bsky.social
October 21, 2026 at 1:24 PM
jamacardiology.com
In patients with #TransthyretinCardiacAmyloidosis, a machine learning-based model predicted all-cause mortality and #HeartFailure hospitalization more accurately than the National Amyloidosis Centre and Mayo Clinic staging systems. #ESCCongress ja.ma/4B2IctV
Machine Learning–Driven Risk Prediction Model in Transthyretin Amyloid Cardiomyopathy
This cohort study develops and validates a machine learning–based prediction model for patients with transthyretin cardiac amyloidosis (ATTR-CM).
ja.ma
October 17, 2026 at 11:00 AM
womenasone.bsky.social
It’s been almost two months since RISE @ ESC Congress 2026 brought hundreds of women and allies together in Munich.

From leadership and AI to research and inclusion, RISE created space to connect, learn and look ahead.

Relive the moments 📽️⬇️

#LetsRISE26 #ESCCongress #CardioSky
October 16, 2026 at 4:00 PM
ascopost.bsky.social
🫀Could mammograms offer insights beyond Breast Cancer?

An AI model showed potential to identify hypertension, ischemic heart disease, and cerebrovascular accident without additional imaging.

🗣️Presented by Viana Copeland, MBBS at #ESCCongress

🔗 https://ow.ly/Qeme50ZLByx
October 15, 2026 at 1:00 PM
womenasone.bsky.social
What does quality really mean in cardiovascular medicine?

At RISE @ ESC Congress 2026, Dr. Silvia Castelletti explored quality metrics in leadership and what it takes to deliver safe, effective, patient-centered care.

Catch up here: womenasone.org/lates...

#LetsRISE26 #ESCCongress #CardioSky
October 12, 2026 at 5:00 PM
womenasone.bsky.social
How can professional societies move beyond conversation and take action to improve women’s health, strengthen women’s leadership, and reduce the global burden of CVD?

Catch up on the RISE @ ESC Congress 2026 session here: womenasone.org/latest-news/...

#LetsRISE26 #ESCCongress #CardioSky
October 7, 2026 at 12:36 PM
womenasone.bsky.social
At the Medtronic-sponsored lunch symposium at RISE @ ESC Congress 2026, the message was clear: equity in CV care and careers must move faster.

Practical solutions, from community BP checks to intentional sponsorship, can help women lead & access care.

#LetsRISE26 #ESCCongress #CardioSky
October 5, 2026 at 5:00 PM
nejm.org
In older adults without cardiovascular disease, treatment with atorvastatin led to a lower risk of major cardiovascular events than placebo at a median of 5.9 years but did not result in longer disability-free survival. Full STAREE trial results: https://nej.md/4ghHPSC

#ESCCongress
October 4, 2026 at 1:00 PM
womenasone.bsky.social
At the Daiichi Sankyo Europe-sponsored lunch symposium at RISE @ ESC Congress 2026, the message was clear.

To close the gender gap in CV medicine, we must move beyond reliance on trailblazers, take women's risks seriously, & include women in clinical trials.

#LetsRISE26 #ESCCongress #CardioSky
October 2, 2026 at 12:30 PM
nejm.org
The STAREE trial tested whether atorvastatin prevents first major cardiovascular events and extends disability-free survival in adults 70 years and older without cardiovascular disease. Research findings are summarized in a new Quick Take video. https://nej.md/4xXoFIG

#ESCCongress
Clockwise from top left: A box labeled "Atorvastatin" with two pills is depicted; an illustration showing a heart with an exclamation mark; a silhouette of a patient with a disability; and a group of five silhouettes representing older patients.
October 1, 2026 at 4:00 PM
womenasone.bsky.social
RISE @ ESC Congress 2026 brought hundreds of women in cardiology and their allies together with world leaders to explore networking, AI, diversity and thought leadership.

Hear the insights and inspiration from the day: womenasone.org/latest-news/...

#LetsRISE26 #ESCCongress #CardioSky
September 28, 2026 at 5:16 PM
nejm.org
In patients with #AFib and intermediate stroke risk, direct oral anticoagulation led to a lower risk of stroke, systemic embolism, major bleeding, or death from cardiovascular causes than no anticoagulation. Full SINGLE-AF trial results and Research Summary: https://nej.md/4ii61XB

#ESCCongress
This image contains an excerpt from the Research Summary "Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk" published in the New England Journal of Medicine. It includes a visual representation of a patient with atrial fibrillation and an intermediate risk of stroke. Patient demographics are detailed as 1803 adults, average age of 60 years. The bottom half contains illustrations of the two treatment options: direct oral anticoagulant (DOAC) therapy or no anticoagulation. A prompt to read the full Research Summary at NEJM.org sits at the bottom.
September 27, 2026 at 7:00 PM
ordofibonacci.bsky.social
ESC TV Morning Show at #ESCCongress - Saturday 29 August 2026
European Society of Cardiology
youtu.be/0ErI05slWkA?...
ESC TV Morning Show at #ESCCongress - Saturday 29 August 2026
YouTube video by European Society of Cardiology
youtu.be
September 25, 2026 at 12:11 AM
ordofibonacci.bsky.social
Day in Focus by ESC TV Today at #ESCCongress - Saturday 29 August 2026
European Society of Cardiology
youtu.be/HSWPROHyZrg?...
Day in Focus by ESC TV Today at #ESCCongress - Saturday 29 August 2026
YouTube video by European Society of Cardiology
youtu.be
September 25, 2026 at 12:12 AM
springermedicine.com
New guidelines, practice-changing trial results, and showcases on how AI is changing CV care - #ESCCongress 2026 offered no shortage of developments for cardiologists to digest.

Our congress hub has the key highlights and expert insights from the meeting.

👉️ buff.ly/5AFTg0f

#CardioSky
September 24, 2026 at 10:54 AM
springermedicine.com
From #ESCCongress 2026 - Dr. Kevin Damman shares the main messages from the new ESC guidelines on the management of cardiovascular disease and chronic kidney disease.

Watch the full interview 👉️ buff.ly/1wiJCiC

#CVD #CKD
September 23, 2026 at 10:54 AM
springermedicine.com
From #ESCCongress 2026: The ACASA-TAVI and NOTION-4 trials have provided conflicting results with regard to the use of direct oral anticoagulants after #TAVI for severe aortic valve stenosis.

👉️ buff.ly/85WZb9Y

#MedNews
Mixed messages on oral anticoagulant therapy after TAVI
The ACASA-TAVI and NOTION-4 trials have provided conflicting results with regard to the use of direct oral anticoagulants after transcatheter aortic valve implantation for severe aortic valve…
buff.ly
September 23, 2026 at 6:25 PM
herzmedizin.bsky.social
🫀 Ungeklärte Synkope: Was bringen frühes EKG-Monitoring und Upfront-Pacing? ASPIRED & Syncope Stopper untersuchten beim #ESCCongress 2026 neue Ansätze im Management von Patienten mit ungeklärter Synkope Prof. L. Eckardt ordnet die Ergebnisse ein.
➡️ herzmedizin.de/fuer-aerzte-...
#DGK #Kardiologie
ASPIRED / Syncope Stopper | ESC Congress 2026
ESC 2026 | ASPIRED / Syncope Stopper: Zwei potenziell praxisverändernde Studien zu ungeklärten Synkopen. Kommentar von Prof. L. Eckardt.
herzmedizin.de
September 22, 2026 at 2:11 PM